ClinicalTrials.gg

Program

pudafensine

Also written as “Pudafensine”, “IP2015” and “IP2015, dose 1”.

Its studies are mostly in Vulvodynia · Pain, led by Initiator Pharma.

Furthest: phase 2, since Jan 21, 20263 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Initiator Pharma31 open or runningphase 2since Jan 21, 2026Nov 20, 2021Dec 31, 2026phase 2 · NCT07391241

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2021First study: phase 1 study in PainFirst studyNCT05181852 · 24 enrolled
  2. Dec 20, 2022Phase 1 study in BioavailabilityNCT05728671 · 12 enrolled
  3. Jan 21, 2026Phase 2 study in VulvodyniaPhase 2 reachedNCT07391241 · 24 enrolled · United Kingdom

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in VulvodyniaNCT07391241

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07391241Vulvodynia · United Kingdom2Active, not recruitingDec 31, 202624
NCT05728671Bioavailability1UNKNOWNMay 16, 202312
NCT05181852Pain1UNKNOWNMay 30, 202224

How it is read

Names in the registry

  • “Pudafensine”, 1 entry
  • “IP2015”, 1 entry
  • “IP2015, dose 1”, 1 entry
  • “IP2015, dose 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.